Release issued 5th April 2000

New HFA Manufacturing Facility

CCL Pharmaceuticals, the contact development and aerosol manufacturing company, are getting ready for the commercialisation of its clients expected new product registrations for HFA metered dose respiratory aerosols (mdis). CCL have converted and refurbished an existing production area to Class 10000 manufacturing standards for mdi bulk manufacturing and aerosol filling. The facility can handle suspensions and solution based formulations and is flameproofed for alcoholic formulations. Single-stage with vacuum crimp, and two-stage filling is also available.

New manufacturing and filling equipment has been installed in February ready for production start-up post validation in Quarter 3 2000

This new facility will operate alongside CCL's existing CFC mdi manufacturing facility, which will continue to produce product for several markets.

For further information on CCL Pharmaceutical's development and manufacturing abilities please contact:

Clive Albany (Managing Director) (mailto:clive.albany@ccl-industries.co.uk)

(28th August 2002) Miza Pharmaceuticals (UK) Limited signs $23 million USD financing deal with GMAC Commercial Credit Limited.

(13th November 2001) Miza Acquires Antigen - Sterile Injectable Pharmaceutical Business in Ireland

(20th September 2001) Miza agreement with Connetics Corporation to provide manufacturing and development services

(1st May 2001) Miza Acquires CCL Industries Pharmaceutical Business Unit

(10th January 2000) HFA MDI developments at CCL Pharmaceuticals